Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459625 | 0.80 | GAA (0.42) | GAAHTTTSHRKMT2AAPEX1 | |
| SCHEMBL8745364 | 0.75 | ALDH1A1 (0.60) | GAAKDM4EHPGDLMNAALDH1A1 | |
| SCHEMBL12083361 | 0.72 | KDM4E (0.63) | GAAHTTTSHRKMT2AKDM4E | |
| SCHEMBL6903284 | 0.71 | TSHR (0.58) | HTTTSHRKMT2AAPEX1KDM4E | |
| SCHEMBL9356632 | 0.70 | GAA (0.42) | GAAHTTTSHRBCAT2KDM4E | |
| SCHEMBL19297581 | 0.70 | ALDH1A1 (0.54) | GAAHTTTSHRKMT2AKDM4E | |
| SCHEMBL1840414 | 0.69 | — | — | |
| SCHEMBL2129167 | 0.69 | TSHR (0.47) | GAAHTTTSHRKMT2AAPEX1 | |
| SCHEMBL19297351 | 0.69 | ALDH1A1 (0.52) | GAAHTTTSHRKDM4EHPGD | |
| SCHEMBL25969064 | 0.69 | KMT2A (0.59) | GAAHTTTSHRKMT2AAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001035899-A9 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-09-19 | — | — | WO | claimed |
| EP-1229925-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001035899-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2001-05-25 | — | — | WO | claimed |
| EP-2867205-B1 | NOVEL CHOLECYSTOKININ RECEPTOR LIGANDS | PNB VESPER LIFE SCIENCE PVT LTD (IN) | 2018-12-19 | — | — | EP | disclosed |
| EP-2867205-A1 | NOVEL CHOLECYSTOKININ RECEPTOR LIGANDS | PNB Vesper Life Science Pvt Limited (IN) | 2015-05-06 | — | — | EP | disclosed |
| US-8921577-B2 | Cholecystokinin receptor ligands | PNB Vesper Life Sciences Pvt. Ltd. (IN) | 2014-12-30 | — | — | US | disclosed |
| WO-2014006629-A1 | NOVEL CHOLECYSTOKININ RECEPTOR LIGANDS | PNB VESPER LIFE SCIENCE PVT LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
| US-20140005248-A1 | NOVEL CHOLECYSTOKININ RECEPTOR LIGANDS | PNB VESPER LIFE SCIENCES PVT LTD. (IN) | 2014-01-02 | — | — | US | disclosed |
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070123718-A1 | Novel 4-amino-2(5H)-furanones | ASTON UNIVERSITY (GB) | 2007-05-31 | — | — | US | disclosed |
| EP-1636197-A1 | NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES | Aston University (GB) | 2006-03-22 | — | — | EP | disclosed |
| EP-1628963-A1 | NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES | Aston University (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-1628966-A2 | 4-AMINO-2(5H)-FURANONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | Aston University (GB) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106310-A1 | NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES | ASTON UNIVERSITY (GB) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106306-A1 | NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES | ASTON UNIVERSITY (GB) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106315-A2 | 4-AMINO-2(5H)-FURANONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | ASTON UNIVERSITY (GB) | 2004-12-09 | — | — | WO | disclosed |
| WO-2001035899-A9 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-09-19 | — | — | WO | disclosed |
| EP-1229925-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001035899-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | CCKAR, CCKBR, GRPR | GAA 4658/4885HTT 3594/4885TSHR 116/4885 |
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | CCKBR, CCKAR, GABRB1 | GAA 2957/4885HTT 4105/4885TSHR 311/4885 |
| US-20140005248-A1 | NOVEL CHOLECYSTOKININ RECEPTOR LIGANDS | CCKAR, CCKBR, GRPR | GAA 4606/4885HTT 2311/4885TSHR 131/4885 |
| US-20070123718-A1 | Novel 4-amino-2(5H)-furanones | CBR1, CBR3, GPR18 | GAA 4780/4885HTT 3331/4885TSHR 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.